OPEN PROSPECTIVE TRIAL INVESTIGATING PHARMACOKINETICS, TOLERABILITY AND SAFETY OF A NEW 10% HUMAN IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE

被引：0
|
作者：
Krivan, G. [1 ]
Koenigs, C. [2 ]
Bernatowska, E. [3 ]
Marodi, L. [4 ]
Erdos, M. [4 ]
Salama, A. [5 ]
Linde, R. [2 ]
机构：
[1] United St Istvan & St Laszlo Hosp, Dept Pediat Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Goethe Univ Frankfurt, Dept Pediat Hemostasis & Immunodeficiency, Frankfurt, Germany
[3] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland
[4] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infectol & Pediat Immunol, H-4012 Debrecen, Hungary
[5] Univ Med Berlin, Inst Transfus Med, Berlin, Germany
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [41] Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
    Richard L. Wasserman
    William Lumry
    James Harris
    Robyn Levy
    Mark Stein
    Lisa Forbes
    Charlotte Cunningham-Rundles
    Isaac Melamed
    Ai Lan Kobayashi
    Wei Du
    Roger Kobayashi
    Journal of Clinical Immunology, 2016, 36 : 590 - 599
  • [42] Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
    Wasserman, Richard L.
    Lumry, William
    Harris, James, III
    Levy, Robyn
    Stein, Mark
    Forbes, Lisa
    Cunningham-Rundles, Charlotte
    Melamed, Isaac
    Kobayashi, Ai Lan
    Du, Wei
    Kobayashi, Roger
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 590 - 599
  • [43] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark R.
    Engl, Werner
    Sharkhawy, Marlies
    Leibl, Heinz
    Puck, Jennifer
    Rubinstein, Arye
    Kobrynski, Lisa
    Gupta, Sudhir
    Grant, Andrew J.
    Ratnayake, Anoshie
    Richmond, Wendell G.
    Church, Joseph
    Yel, Leman
    Gelmont, David
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 571 - 582
  • [44] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
    Richard L. Wasserman
    Isaac Melamed
    Mark R. Stein
    Werner Engl
    Marlies Sharkhawy
    Heinz Leibl
    Jennifer Puck
    Arye Rubinstein
    Lisa Kobrynski
    Sudhir Gupta
    Andrew J. Grant
    Anoshie Ratnayake
    Wendell G. Richmond
    Joseph Church
    Leman Yel
    David Gelmont
    Journal of Clinical Immunology, 2016, 36 : 571 - 582
  • [45] Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
    Wasserman, R. L.
    Irani, A. -M.
    Tracy, J.
    Tsoukas, C.
    Stark, D.
    Levy, R.
    Chen, J.
    Sorrells, S.
    Roberts, R.
    Gupta, S.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (03): : 518 - 526
  • [46] Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies
    Bleasel, K.
    Heddle, R.
    Hissaria, P.
    Stirling, R.
    Stone, C.
    Maher, D.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (03) : 252 - 259
  • [47] EPIDEMIOLOGY PROFILE OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE (PID) UNDER REGULAR THERAPY WITH OR WITHOUT INTRAVENOUS IMMUNOGLOBULIN (IVIG) REPLACEMENT IN BRAZIL
    Lawrence, T. C.
    Scancetti, F.
    Silva, A. M. R.
    Goudouris, E.
    Ouricuri, A. L.
    Costa-Carvalho, B. T.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 399 - 399
  • [48] Efficacy and Safety of Tegeline Liquido (ClairYg) a 5 % Ready-to-Use Intravenous Immunoglobulin (IVIg), in Adult Patients with Primary Immunodeficiency (PID)
    Jean-Francois, Viallard
    Sophie, Puget
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S48 - S49
  • [49] A new intravenous immune globulin, 10% liquid, triple virus reduced (IGIV, 10% TVR) - Pharmacokinetics, efficacy and safety in patients with primary immunodeficiency
    Leibl, Heinz
    Church, Joseph A.
    Stein, Mark R.
    Melamed, Isaac R.
    Rubinstein, Ayre
    Schneider, Lynda C.
    Wasserman, Richard L.
    Pavlova, Borislava G.
    Birthistle, Karl
    Mancini, Marianne
    Fritsch, Sandor
    Moore-Perry, Kerry
    Ehrlich, Hartmut J.
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 500 - 500
  • [50] LONG-TERM SAFETY AND PHARMACOKINETICS OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): PHASE 3 EXTENSION STUDY IN PRIMARY IMMUNODEFICIENCY DISEASE
    Melamed, I.
    Wasserman, R. L.
    Stein, M.
    Rubenstein, A.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 132 - 133
12345